Showing 7091-7100 of 7563 results for "".
- Miramar Labs to Launch miraSmooth Treatment with FDA Clearance of miraDry For Permanent Reduction of Underarm Hairhttps://practicaldermatology.com/news/miramar-labs-to-launch-mirasmooth-treatment-with-fda-clearance-of-miradry-for-permanent-reduction-of-underarm-hair/2458906/Miramar Labs’ miraDry® System received FDA clearance for the treatment of unwanted underarm hair, and permanent reduction of underarm hair of all colors. Miramar Lab's proprietary miraWave® technology—use of precisely controlled microwave energy—is the founda
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- Investigational Foam May Offer Itch Relief for Psoriasis Patientshttps://practicaldermatology.com/news/investigational-foam-may-offer-itch-relief-for-psoriasis-patients/2458931/An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congress of Dermatology. According to the Phase 3 clinical trial, 426 psoriasis patients were split int
- InMed Pharmaceuticals Files Provisional Patent for Novel Compounds to Treat Epidermolysis Bullosa Simplexhttps://practicaldermatology.com/news/inmed-pharmaceuticals-files-provisional-patent-for-novel-compounds-to-treat-epidermolysis-bullosa-simplex/2458939/InMed Pharmaceuticals Inc. filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. Dr. Sazzad Hossain, InMed Pha
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- TV Star, Mother of Four Larsa Pippen Shares Her UltraShape Storyhttps://practicaldermatology.com/news/ultrashape/2458944/UltraShape’s newest devotee, Larsa Pippen, Real Housewives of Miami Alumni, wife of six-time world champion NBA star Scottie Pippen, and fitness enthusiast, recently talked about her UltraShape experience, saying “UltraShape gives me more confidence. I eat well and exercise regularly,
- New Research Finds TriCalm Hydrogel's Itch Relief Superior to Leading OTC Treatmentshttps://practicaldermatology.com/news/new-research-finds-tricalm-hydrogels-itch-relief-superior-to-leading-otc-treatments/2458949/A study conducted to assess the antipruritic effect of over-the-counter (OTC) steroid-free topical hydrogel formulation TriCalm® in reducing itch intensity and duration, has been published in Clinical, Cosmetic, and Investigational Dermatology. The study, which utilized a co
- Viscot Medical Introduces Soffzone Neutral Zone Trayshttps://practicaldermatology.com/news/viscot-medical-introduces-soffzone-neutral-zone-trays/2458950/Intended to reduce the risk of sharps injuries, Viscot Medical’s Soffzone™ Neutral Zone trays were designed by a plastic surgeon for plastic surgeons. According to Viscot, the Soffzone™ Neutral Zone can be easily integrated into a sharps safety
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s